EDF Ventures

EDF Ventures is a venture capital firm based in Ann Arbor, Michigan, founded in 1987. The firm specializes in early-stage and growth investments, primarily in the healthcare and information technology sectors. In healthcare, EDF Ventures focuses on technologies related to pharmaceuticals, medical devices, diagnostics, and solutions for conditions such as cardiology, diabetes, neurology, and obesity. Its information technology investments include areas like mobility, security, data management, and communications networks. While the firm prefers to invest in companies located in the Midwest and Southern California, it is particularly interested in early-stage investments linked to research universities in the Great Lakes region. Typically, EDF Ventures makes initial investments ranging from $500,000 to $1.5 million and can follow up with additional investments of $3.5 million to $5 million. The firm has built a strong network to support its portfolio companies by aiding in management, partnerships, and additional funding opportunities.

Mary Campbell

Managing Director

46 past transactions

IntelePeer

Series D in 2013
IntelePeer is a communications automation platform that leverages generative AI to streamline customer interactions. It helps businesses reduce operational costs while improving customer experiences through efficient automation solutions. The platform integrates seamlessly with existing systems to optimize communication processes across various channels.

Direct Flow Medical

Venture Round in 2012
Direct Flow Medical is a medical device company developing a percutaneous aortic tissue valve prosthesis to provide patients requiring treatment of cardiac valve insufficiency with a safe and effective percutaneous option. Approximately 1.2 million people over the age of 65 have calcified aortic valves, yet only an estimated 150,000 are surgically treated each year.

TransCorp Spine

Series A in 2011
TransCorp Spine manufactures medical devices and procedures to restore spinal function and preserve healthy tissue. Its product includes SpinePort, a MIS access system. David Lowry, Des O'Farrell, and Scott Tuinstra founded TransCorp Spine in 2008. It has its headquarters in Byron Center in Michigan.

Sonoma Orthopedics

Series D in 2011
Sonoma Orthopedic Products designs, develops, and delivers proprietary orthopedic implants for physicians to address problematic fractures. The WaviBodyâ„¢ technology platform allows for quick, minimally invasive surgical solutions for active patients. Direct to Bone...Back To Life.

Abionyx Pharma

Series C in 2010
AbIONYX Pharma is a biotechnology company that is focused on providing innovative therapies for indications without effective or existing treatments, even the rarest ones. They provide drugs for the treatment of renal and ophthalmological diseases on a daily basis.

Direct Flow Medical

Series C in 2009
Direct Flow Medical is a medical device company developing a percutaneous aortic tissue valve prosthesis to provide patients requiring treatment of cardiac valve insufficiency with a safe and effective percutaneous option. Approximately 1.2 million people over the age of 65 have calcified aortic valves, yet only an estimated 150,000 are surgically treated each year.

ValenTx

Series B in 2009
ValenTx is a development-stage medical device company that focuses on minimally-invasive methods for the treatment of morbid obesity. The company was founded in 2002 and headquartered in Maple Grove, Minnesota.

Lycera

Series A in 2009
Lycera is a preclinical-stage biopharma company focused on small molecule immunomodulators for the treatment of rheumatoid arthritis, lupus erythematosus, and inflammatory bowel disease Lycera's first-in-class drugs are designed to treat immune disorders. The company's technology platforms include proprietary small molecules that modulate a target, which is central to cellular bioenergetics along with molecules that target the Th17 pathway. Drugs that emerge from the Lycera pipeline will represent first-in-class agents that have the potential for first-in-class oral efficacy without the adverse effects of current standard-of-care antiproliferative and immunosuppressive agents.

Vontoo

Series B in 2009
Vontoo brings the emotion, enthusiasm and energy of the human voice to one-to-one marketing communication. Vontoo enables organizations to create, send and track voice messages tailored to the recipient's interests. Vontoo is accessible over an Internet web browser, anytime or anywhere, and can instantly send from one to millions of automated calls to help clients drive revenues, reduce costs, collect cash faster and enhance customer relationships. Vontoo is funded from multiple sources, including private investors and venture capital firm, EDF Ventures. Vontoo is privately owned and headquartered in Indianapolis.

Perfinity Biosciences

Venture Round in 2008
Perfinity Biosciences offers consumable kits and automated instrument solutions that simplify protein sample preparation. Perfinity Biosciences products enable unprecedented levels of reproducibility and speed in easy-to-use formats. Perfinity's products include beads for proteomics applications and a solution testing device that is compatible with a wide range of workflows like solid tissues, gels, and sample pellets.

HandyLab

Series D in 2008
HandyLab is a medical technology company that develops and manufactures molecular diagnostic assays and automation platforms The company’s proprietary platform reduces the time, cost, and complexity of testing while improving the quality of results. Using patented real-time microfluidic PCR technology, its products are positioned to decentralize nucleic acid testing. HandyLab was founded in 2000 and is based in Ann Arbor, Michigan. It was acquired by Becton, Dickinson and Company in 2009.

Eleme Medical

Series C in 2008
Elemé Medical, Inc. is a venture backed aesthetics company dedicated to providing market-leading technology in all areas of body shaping. The newly launched SmoothShapes® XV will revolutionize how cellulite is treated and introduce exciting new protocols for pre and post liposuction care. With 50% more laser power, SmoothSpeed™ audible & visual treatment guidance and a portable, sleek console design, SmoothShapes XV is an ideal way to add non-invasive body shaping to a practice. SmoothShapes XV is the newest product launched by the Company and joins the original SmoothShapes launched in 2008, both products are a CE Marked, FDA-cleared medical devices for the temporary reduction in the appearance of cellulite. Both SmoothShapes systems are based on the company's proprietary Photomology® platform — a process that treats cellulite and subcutaneous fat by combining dynamic light and laser energy along with mechanical manipulation (vacuum and massage). The system addresses the physical manifestations of cellulite and its underlying causes providing long lasting results that patients can see and feel. Targets include plastic surgeons, aesthetic dermatologists, medical spas and other aesthetic physicians. According to Global Body Shaping Market Analysis, body shaping is one of the top growth areas in the Aesthetics market with 19% growth through the year 2012. The global aesthetics market is projected to grow from $5.0 billion in 2008 to $8.1 billion by 2011.

Alure Medical

Series A in 2008
Alure Medical focuses on the development and commercialization of percutaneous soft tissue lift devices and delivery systems for plastic surgery utilizing patent-pending technologies.

Nanosolar

Series D in 2008
Nanosolar prints solar cells and assembles panels to enable the most cost-efficient solar electricity. Nanosolars proprietary approach to printing CIGS (Copper, Indium, Gallium, Selenium) and nanoparticle inks using an annealing process minimizes the use of expensive, high vacuum deposition manufacturing equipment. This allows the Company to utilize equipment from the industrial printing and roll-to-roll manufacturing industries to produce solar-electric foil at high speeds, bringing the economics of printing to the world of solar PV semiconductor manufacturing.

IntelePeer

Series B in 2008
IntelePeer is a communications automation platform that leverages generative AI to streamline customer interactions. It helps businesses reduce operational costs while improving customer experiences through efficient automation solutions. The platform integrates seamlessly with existing systems to optimize communication processes across various channels.

Greenplum Software

Series C in 2008
Greenplum, Inc., a data warehousing company, develops database software for business intelligence and data warehousing applications. It offers Greenplum Database that supports multi-terabyte data warehousing demands; and Greenplum Network, a customer and partner portal that delivers instant download access to database products. The company primarily serves telecommunications and banking industries.

Direct Flow Medical

Series B in 2007
Direct Flow Medical is a medical device company developing a percutaneous aortic tissue valve prosthesis to provide patients requiring treatment of cardiac valve insufficiency with a safe and effective percutaneous option. Approximately 1.2 million people over the age of 65 have calcified aortic valves, yet only an estimated 150,000 are surgically treated each year.

RockeTalk

Series A in 2007
RockeTalk was founded with a vision of enabling all people to more easily express themselves and communicate with their friends, family and new acquaintances, as well as capture, share, and discover their content…all over their mobile phones. RockeTalk has developed and launched a social media platform and mobile phone client applications that provide a variety of fast, easy-to-use multimedia services. Users can create any combination of text, voice, photo, and video messages, share with any contacts, join communities and chat with individuals and groups, and access a variety of entertainment and content. RockeTalk makes communication between individuals and groups easy and rich, and facilitates a new form of self-expression that informs, entertains and connects people through the media they create.

BioSET

Venture Round in 2007
BioSurface Engineering Technologies, Inc., also known as BioSET, engages in developing proprietary therapeutic peptides as medical devices to improve bone and soft tissue repair. The company focuses on developing devices for orthobiologics applications. Its products include AMPLEX, an implantable combination device of the B2A peptide and a synthetic ceramic scaffold for use as a surgical bone graft implant for lumbar degenerative disc disease, as well as for use in spine, cervical spine, and foot and ankle fusion surgeries. The company also develops products for sports medicine applications based on its F2A peptide; and peptide signaling molecules and various scaffold biomaterials for use in musculoskeletal applications, including trauma, fracture repair, and other soft tissue treatments. BioSurface Engineering Technologies, Inc. was founded in 2001 and is based in Rockville, Maryland.

Sonoma Orthopedics

Series B in 2007
Sonoma Orthopedic Products designs, develops, and delivers proprietary orthopedic implants for physicians to address problematic fractures. The WaviBodyâ„¢ technology platform allows for quick, minimally invasive surgical solutions for active patients. Direct to Bone...Back To Life.

Sonoma Orthopedics

Series A in 2007
Sonoma Orthopedic Products designs, develops, and delivers proprietary orthopedic implants for physicians to address problematic fractures. The WaviBodyâ„¢ technology platform allows for quick, minimally invasive surgical solutions for active patients. Direct to Bone...Back To Life.

Arxan Technologies

Series C in 2007
Arxan, a global trusted leader providing the industry’s most comprehensive application protection solutions, works with organizations looking to protect critical applications that deployed “into the wild.” Arxan currently protects more than one billion application instances across many industries including financial services, mobile payments, healthcare,automotive, gaming, and entertainment. Unlike legacy security providers that relying on perimeter-based barriers to keep bad actors out or that require device management controls, Arxan products protect at the application-level from the inside out. This approach protects the source and binary code to expand the corporate perimeter of trust. Arxan provides a broad range of patented security capabilities such as a dynamic app policy engine, code hardening, obfuscation, white-box cryptography and encryption, and threat analytics.

Greenplum Software

Series B in 2007
Greenplum, Inc., a data warehousing company, develops database software for business intelligence and data warehousing applications. It offers Greenplum Database that supports multi-terabyte data warehousing demands; and Greenplum Network, a customer and partner portal that delivers instant download access to database products. The company primarily serves telecommunications and banking industries.

Abionyx Pharma

Series B in 2006
AbIONYX Pharma is a biotechnology company that is focused on providing innovative therapies for indications without effective or existing treatments, even the rarest ones. They provide drugs for the treatment of renal and ophthalmological diseases on a daily basis.

Lycera

Seed Round in 2006
Lycera is a preclinical-stage biopharma company focused on small molecule immunomodulators for the treatment of rheumatoid arthritis, lupus erythematosus, and inflammatory bowel disease Lycera's first-in-class drugs are designed to treat immune disorders. The company's technology platforms include proprietary small molecules that modulate a target, which is central to cellular bioenergetics along with molecules that target the Th17 pathway. Drugs that emerge from the Lycera pipeline will represent first-in-class agents that have the potential for first-in-class oral efficacy without the adverse effects of current standard-of-care antiproliferative and immunosuppressive agents.

ValenTx

Series A in 2006
ValenTx is a development-stage medical device company that focuses on minimally-invasive methods for the treatment of morbid obesity. The company was founded in 2002 and headquartered in Maple Grove, Minnesota.

Greenplum Software

Series A in 2006
Greenplum, Inc., a data warehousing company, develops database software for business intelligence and data warehousing applications. It offers Greenplum Database that supports multi-terabyte data warehousing demands; and Greenplum Network, a customer and partner portal that delivers instant download access to database products. The company primarily serves telecommunications and banking industries.

Direct Flow Medical

Series A in 2005
Direct Flow Medical is a medical device company developing a percutaneous aortic tissue valve prosthesis to provide patients requiring treatment of cardiac valve insufficiency with a safe and effective percutaneous option. Approximately 1.2 million people over the age of 65 have calcified aortic valves, yet only an estimated 150,000 are surgically treated each year.

Abionyx Pharma

Series A in 2005
AbIONYX Pharma is a biotechnology company that is focused on providing innovative therapies for indications without effective or existing treatments, even the rarest ones. They provide drugs for the treatment of renal and ophthalmological diseases on a daily basis.

BioSET

Series B in 2004
BioSurface Engineering Technologies, Inc., also known as BioSET, engages in developing proprietary therapeutic peptides as medical devices to improve bone and soft tissue repair. The company focuses on developing devices for orthobiologics applications. Its products include AMPLEX, an implantable combination device of the B2A peptide and a synthetic ceramic scaffold for use as a surgical bone graft implant for lumbar degenerative disc disease, as well as for use in spine, cervical spine, and foot and ankle fusion surgeries. The company also develops products for sports medicine applications based on its F2A peptide; and peptide signaling molecules and various scaffold biomaterials for use in musculoskeletal applications, including trauma, fracture repair, and other soft tissue treatments. BioSurface Engineering Technologies, Inc. was founded in 2001 and is based in Rockville, Maryland.

OXAND

Venture Round in 2004
Oxand is an international consulting and solutions provider with proven capabilities, knowledge and tools for capital intensive assets. As an independent company, they deliver risk-informed decision support information that improves returns across the life cycle of their clients’ assets. Their worldwide clients are investors, owners, contractors and managers in Energy (Nuclear, Oil & Gas, Renewables), Transport (Railways, Roads & Waterways) and Public/Private Properties (Public Infrastructures, Private & Industrial assets). Enhancing their clients’ reputations by supporting better decisions, with more than 1,150 billion Euros worth of analysed assets, they have experience that includes optimising the life cycle decisions and reducing costs by 10 to 30%; making possible life extension versus renewals; and reducing costly delays of large projects. Their solutions, supported by their Simeo™ technologies and data libraries, are fully compliant with best standards (as ISO 55000, ISO 31000, ISO 15288, NEC3…). They deliver tailored consultancy, training and IT solutions.

HandyLab

Series C in 2004
HandyLab is a medical technology company that develops and manufactures molecular diagnostic assays and automation platforms The company’s proprietary platform reduces the time, cost, and complexity of testing while improving the quality of results. Using patented real-time microfluidic PCR technology, its products are positioned to decentralize nucleic acid testing. HandyLab was founded in 2000 and is based in Ann Arbor, Michigan. It was acquired by Becton, Dickinson and Company in 2009.

Xtera

Venture Round in 2003
Xtera is a privately held network equipment and services company, and a leading provider of optical networks for terrestrial and subsea applications. Over the last year Xtera has succeeded in expanding its customer base and product portfolio in both existing and new markets. The AscenVision acquisition continues this strategic growth, extending Xtera's product portfolio beyond the optical layer. Xtera supplies both un-repeatered and repeatered systems, using our high-performance optical amplifiers to deliver traffic directly inland to cities. They create novel solutions that are tailored to each individual customer, whether providing a full turnkey system, an open architecture design, or a supply of a particular product or service.

Arxan Technologies

Series B in 2003
Arxan, a global trusted leader providing the industry’s most comprehensive application protection solutions, works with organizations looking to protect critical applications that deployed “into the wild.” Arxan currently protects more than one billion application instances across many industries including financial services, mobile payments, healthcare,automotive, gaming, and entertainment. Unlike legacy security providers that relying on perimeter-based barriers to keep bad actors out or that require device management controls, Arxan products protect at the application-level from the inside out. This approach protects the source and binary code to expand the corporate perimeter of trust. Arxan provides a broad range of patented security capabilities such as a dynamic app policy engine, code hardening, obfuscation, white-box cryptography and encryption, and threat analytics.

Arbor Networks

Series B in 2002
Company Description Arbor Networks secures the world's most demanding and complex networks from DDoS attacks and advanced threats. Solutions Overview Arbor Networks customers gain a micro view of their own network, through their suite of products, combined with a macro view of global Internet traffic and emerging threats, through their ATLAS threat intelligence infrastructure. See, understand and solve more security threats with Arbor Networks. ATLAS provides a comprehensive, aggregated view of global traffic and threats. 330+ service provider customers contribute 120 Tbps of global traffic intelligence, enabling Arbor's Security Engineering & Response Team (ASERT) to develop threat protections that are delivered directly into customer products to stop DDoS attacks and malware campaigns. Arbor DDoS Solutions are proven on the world's most demanding networks. their portfolio offers complete deployment flexibility to meet the needs of any organization, from virtual solutions, network-embedded solutions within Cisco's ASR 9000 routers, to appliances for enterprises and carrier-class scrubbing centers. In Arbor Cloud, they offer a best-practice DDoS defense service that tightly integrates on-premises and cloud-based mitigation in a single solution. Ensure the availability of your critical infrastructure with the world's most broadly deployed DDoS mitigation technology. Arbor Advanced Threat Solutions leverage integrated Netflow and Packet Capture technology for network-wide situational awareness, broad and deep traffic visibility and security intelligence that transforms threat detection and incident response through real-time and historical insights, stunning visualization and forensics. Protect your most critical assets from advanced threats that are within your network right now.

HandyLab

Series B in 2002
HandyLab is a medical technology company that develops and manufactures molecular diagnostic assays and automation platforms The company’s proprietary platform reduces the time, cost, and complexity of testing while improving the quality of results. Using patented real-time microfluidic PCR technology, its products are positioned to decentralize nucleic acid testing. HandyLab was founded in 2000 and is based in Ann Arbor, Michigan. It was acquired by Becton, Dickinson and Company in 2009.
Virtual Silicon Technology is a provider of SIP solutions to manufacturers and designers of system-on-chip semiconductors.

MetaMatrix

Series C in 2001
MetaMatrix is an U.S.-based technology company that created the first true Enterprise Information Integration (EII) software product.

IntraLase

Venture Round in 2000
IntraLase Corporation is a leader in the first step of LASIK surgery, the most common means of surgical vision correction. They design, develop and market a laser, related software and disposable devices used to create a cut of tissue across the cornea of a patient’s eye, or a corneal flap, which is the first step in LASIK surgery. Their advanced laser technology improves the safety, precision and visual acuity of LASIK surgery by providing a computer-controlled laser solution as an alternative to the traditional method of creating the corneal flap using a hand-held mechanical, metal-bladed device called a microkeratome. They believe their product offering will become the new standard of care for corneal flap creation. As of April 2, 2007, IntraLase Corp. was acquired by Advanced Medical Optics Inc.

Ican

Venture Round in 2000
Ican Inc., is a provider of Internet-based information and tools for health professionals.

Ican

Venture Round in 2000
Ican provides Internet-based information and tools for health professionals.

Alfalight

Series A in 2000
Alfalight designs and manufactures high-power diode lasers for the industrial, defense, and telecommunications markets. Alfalight's innovative technology is based on advanced aluminum-free active region (ALFA) laser structures, enabling the manufacture of laser diodes with exceptionally high reliability and industry-leading efficiency.

Centromine

Venture Round in 1999
Centromine offers a browser-based, internet-accessed, enterprise-wide software applications and services for the health care market. Its applications allow behavioral health care programs and providers to manage the delivery and associated quality and cost of services completely over the internet.

IntraLase

Series C in 1999
IntraLase Corporation is a leader in the first step of LASIK surgery, the most common means of surgical vision correction. They design, develop and market a laser, related software and disposable devices used to create a cut of tissue across the cornea of a patient’s eye, or a corneal flap, which is the first step in LASIK surgery. Their advanced laser technology improves the safety, precision and visual acuity of LASIK surgery by providing a computer-controlled laser solution as an alternative to the traditional method of creating the corneal flap using a hand-held mechanical, metal-bladed device called a microkeratome. They believe their product offering will become the new standard of care for corneal flap creation. As of April 2, 2007, IntraLase Corp. was acquired by Advanced Medical Optics Inc.

Pixelworks

Venture Round in 1999
Pixelworks is a fabless semiconductor company that designs, develops, and markets innovative video and pixel processing chips and software for high-end display applications, including digital projection, large screen LCD flat panels, and digital signage. Its solutions leverage proprietary core technologies that enable digital display and projection device manufacturers to differentiate their products with a consistently high level of video quality, regardless of the content's source or format. Additionally, its solutions facilitate rapid development and customization of display devices, thus reducing time to market for our customers.

IntraLase

Venture Round in 1999
IntraLase Corporation is a leader in the first step of LASIK surgery, the most common means of surgical vision correction. They design, develop and market a laser, related software and disposable devices used to create a cut of tissue across the cornea of a patient’s eye, or a corneal flap, which is the first step in LASIK surgery. Their advanced laser technology improves the safety, precision and visual acuity of LASIK surgery by providing a computer-controlled laser solution as an alternative to the traditional method of creating the corneal flap using a hand-held mechanical, metal-bladed device called a microkeratome. They believe their product offering will become the new standard of care for corneal flap creation. As of April 2, 2007, IntraLase Corp. was acquired by Advanced Medical Optics Inc.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.